Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric evolocumab add-on safety and efficacy study in familial hypercholesterolemia
NL-OMON55627Active, not recruiting
- Sponsor
- Amgen
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of evolocumab in familial hypercholesterolemia (FH), sponsored by Amgen. Primary endpoint: Treatment-emergent adverse events. Started Apr 2017; status: active, not recruiting.
02
Drugs
evolocumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON55627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55627.